• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    AN2 Therapeutics, Inc. - Common Stock (NQ:ANTX)

    4.930 -0.270 (-5.19%)
    Streaming Delayed Price Updated: 2:20 PM EDT, Jun 29, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 153,728
    Open 5.230
    Bid (Size) 4.910 (300)
    Ask (Size) 4.950 (300)
    Prev. Close 5.200
    Today's Range 4.690 - 5.260
    52wk Range 1.000 - 6.910
    Shares Outstanding 21,928,452
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease
    From AN2 Therapeutics, Inc.
    Via Business Wire
    News headline image
    AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference
    From AN2 Therapeutics, Inc.
    Via Business Wire

    Performance

    YTD
    +344.1%
    +344.1%
    1 Month
    +13.9%
    +13.9%
    3 Month
    +42.5%
    +42.5%
    6 Month
    +352.3%
    +352.3%
    1 Year
    +365.1%
    +365.1%

    More News

    Read More
    AN2 Therapeutics Inc (NASDAQ:ANTX) Pipeline Progress Outshines Slight Q1 Earnings Miss ↗
    Via Chartmill
    News headline image
    AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights
    From AN2 Therapeutics, Inc.
    Via Business Wire
    News headline image
    AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum
    From AN2 Therapeutics, Inc.
    Via Business Wire
    News headline image
    AN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Complex Lung Disease
    From AN2 Therapeutics, Inc.
    Via Business Wire
    News headline image
    AN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific Highlights
    From AN2 Therapeutics, Inc.
    Via Business Wire
    Top stock movements in today's session. ↗
    Via Chartmill
    News headline image
    AN2 Therapeutics Stock Jumps 90% Monday: What's Driving The Action? ↗
    Via Benzinga
    News headline image
    ENDRA Life Sciences (NASDAQ: NDRA): The GLP-1 Healthcare Boom Offering Tremendous Opportunity Watch HIMS, ANTX, ATAI, PURR Now!
    Via AB Newswire
    News headline image
    ANTX Stock Records Biggest Ever Single Day Gain, Surges 500% Over Past Four Sessions – What Triggered This Smashing Rally? ↗
    Via Stocktwits
    In today's session, these stocks are experiencing unusual volume. ↗
    Via Chartmill
    Monday's session: top gainers and losers ↗
    Via Chartmill
    News headline image
    AN2 Therapeutics Announces $40 Million Private Placement Financing
    From AN2 Therapeutics, Inc.
    Via Business Wire
    Here are the top movers in Friday's session. ↗
    Via Chartmill
    Which stocks are moving on Friday? ↗
    Via Chartmill
    News headline image
    AN2 Therapeutics Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera (PV)
    From AN2 Therapeutics, Inc.
    Via Business Wire
    News headline image
    AN2 Therapeutics to Participate in Fireside Chat at Leerink Global Healthcare Conference
    From AN2 Therapeutics, Inc.
    Via Business Wire
    News headline image
    AN2 Therapeutics Announces FDA Clearance to Proceed with 90-Patient Investigator-Initiated Trial (IIT) of Epetraborole in Patients with M. abscessus Lung Disease
    From AN2 Therapeutics, Inc.
    Via Business Wire
    News headline image
    AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business and Scientific Highlights
    From AN2 Therapeutics, Inc.
    Via Business Wire
    News headline image
    AN2 Therapeutics Announces Research Collaboration With GSK to Advance Boron-Based LeuRS-Inhibitors Targeting Tuberculosis (TB)
    From AN2 Therapeutics, Inc.
    Via Business Wire
    News headline image
    AN2 Therapeutics to Participate in Fireside Chat at Evercore HealthCONx Conference
    From AN2 Therapeutics, Inc.
    Via Business Wire
    News headline image
    12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
    Via Benzinga
    News headline image
    AN2 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business and Scientific Highlights
    From AN2 Therapeutics, Inc.
    Via Business Wire
    News headline image
    AN2 Therapeutics Commences First-in-Human Clinical Trial of Oral AN2-502998 for Chagas Disease
    From AN2 Therapeutics, Inc.
    Via Business Wire

    Frequently Asked Questions

    Is AN2 Therapeutics, Inc. - Common Stock publicly traded?
    Yes, AN2 Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does AN2 Therapeutics, Inc. - Common Stock trade on?
    AN2 Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for AN2 Therapeutics, Inc. - Common Stock?
    The ticker symbol for AN2 Therapeutics, Inc. - Common Stock is ANTX on the Nasdaq Stock Market
    What is the current price of AN2 Therapeutics, Inc. - Common Stock?
    The current price of AN2 Therapeutics, Inc. - Common Stock is 4.930
    When was AN2 Therapeutics, Inc. - Common Stock last traded?
    The last trade of AN2 Therapeutics, Inc. - Common Stock was at 06/29/26 02:20 PM ET
    What is the market capitalization of AN2 Therapeutics, Inc. - Common Stock?
    The market capitalization of AN2 Therapeutics, Inc. - Common Stock is 108.11M
    How many shares of AN2 Therapeutics, Inc. - Common Stock are outstanding?
    AN2 Therapeutics, Inc. - Common Stock has 108M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.